Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
Janus kinases
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "Janus kinases" in MCE Product Catalog:
29
Target:
Research Areas:
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .
3
Target:
Research Areas:
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively .
3
3 Cited Publications
Synonyms: PF-06700841 P-Tosylate
Target:
Research Areas:
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively .
1
Target:
Research Areas:
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .
1
1 Cited Publications
Tofacitinib metabolite-1 is a metabolite of Tofacitinib and a JAK3 inhibitor .
1
Target:
Research Areas:
Atinvicitinib is an orally active and selective JAK1 inhibitor. Atinvicitinib blocks signaling of JAK1-dependent pruritogenic and pro-inflammatory cytokines, including those in the IL-31, IL-4, and IL-13 pathways. Atinvicitinib can be used for the researches of pruritus associated with allergic dermatitis and canine atopic dermatitis .
Cat. No.: HY-50856S
CAS No.: 1513883-39-0
Synonyms: CTP-543; Ruxolitinib-d8; INCB18424-d8
Target:
Research Areas:
Deuruxolitinib (CTP-543; Ruxolitinib-d8) is a deuterated analog of Ruxolitinib (HY-50856) and an orally active, selective inhibitor of JAK1 and JAK2. Deuruxolitinib blocks Janus kinase-mediated cytokine receptor signaling and proinflammatory cytokine gene expression. Deuruxolitinib is primarily metabolized in the liver via CYP2C9. Deuruxolitinib promotes scalp hair regrowth in severe chronic alopecia areata. Deuruxolitinib is used in alopecia areata-related research .
Cat. No.: HY-P10373
CAS No.: 1259928-08-9
Target:
Research Areas:
Target:
Research Areas:
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM.
Cat. No.: HY-W394903
CAS No.: 1257705-09-1
Target:
Research Areas:
GS-829845 is a is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life .
Cat. No.: HY-P1111
CAS No.: 222018-18-0
Target:
Research Areas:
Cat. No.: HY-N2521
CAS No.: 52328-97-9
Synonyms: FLLL31
SJ10542 is a potent and selective JAK2/3 PROTAC degrader, with DC50 values of 14 nM and 11 nM against JAK2 and JAK3, respectively. SJ10542 exhibits anti-tumor activity and can be used for research on acute lymphoblastic leukemia .
Synonyms: PG-011
Target:
Research Areas:
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib shows anti-inflammatory activity .
Target:
Research Areas:
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .
Cat. No.: HY-159827
CAS No.: 2641636-52-2
Target:
Research Areas:
Cenacitinib is a potent Janus kinase inhibitor. Cenacitinib shows anti-inflammatory activity .
Research Areas:
iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .
Cat. No.: HY-19569A
CAS No.: 1607431-21-9
Synonyms: ABT-494 tartrate tetrahydrate
Target:
Research Areas:
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .
Cat. No.: HY-159536
CAS No.: 1299417-07-4
Synonyms: KN-002; VR-588
Target:
Research Areas:
Frevecitinib (KN-002; VR-588) is a lung-selective pan-JAKs (i.e., JAK1, JAK2, JAK3, TYK2) inhibitor. Frevecitinib reduces sputum eosinophil levels. Frevecitinib reduces fractional exhaled nitric oxide (FeNO) levels. Frevecitinib is used for the research of moderate-to-severe asthma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
